Latest Derivatives News

HITIQ Limited’s largest shareholder, Harmil Angel Investments, is converting $1.6 million in convertible notes into shares, while the company revamps its advisory mandate to attract US investors.

Pacific Current Group reports a 6.1% increase in total Funds Under Management to A$30 billion as of December 31, 2024, despite a decline in USD-denominated assets and exits from two boutique managers.

Pancontinental Energy reports encouraging technical progress on its PEL 87 project with improved reservoir confidence and ongoing drilling success in Namibia’s Orange Basin, underpinning a solid cash position.

EVZ Limited has issued earnings guidance for the first half of FY2025, forecasting revenue between $53 million and $55 million and EBITDA ranging from $2.4 million to $2.6 million based on preliminary figures.

OZZ Resources reports a promising scoping study for its Maguires Reward gold project, highlighting potential positive cash flow despite limited exploration activity during the December 2024 quarter.

Far East Gold Ltd has reported a maiden JORC resource estimate of 540,000 ounces of gold at its Idenburg project in Indonesia, alongside a conditional acquisition agreement and nearly A$10 million in funding from strategic investor Xingye Gold.

Amplia Therapeutics reports encouraging progress in its Phase 2a ACCENT trial for pancreatic cancer, with nine confirmed partial responses and ongoing patient recruitment. The company also strengthens its financial position with a $13 million capital raise to support further clinical development.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

Change Financial Limited reported a robust Q2 FY25 with revenue surging 53% year-on-year, driven by its expanding PaaS platform, while strategically exiting its loss-making US operations to sharpen focus on Australia and New Zealand.

Torque Metals and Aston Minerals have updated shareholders on their merger, confirming the share exchange ratio and appointing an independent expert to assess the deal's fairness.

Entyr Limited has ramped up tyre receivals and processing volumes in the December quarter, alongside securing new supply and offtake agreements as it prepares for ASX reinstatement. The company’s ongoing plant upgrades and strategic partnerships signal a potential turnaround in its operational and financial trajectory.

Tissue Repair Limited has commenced patient randomisation in its Phase 3 trial of TR987®, targeting chronic venous leg ulcers, aiming to confirm promising earlier results and potentially transform wound healing treatment.